My humble opinion only.
Even during all the commotion surrounding IMM-124E’s potential re. Ash/Nash. IMM-529 and it’s efficacy on CDiff. was always showing greater potential
Whilst FDA approval of IMM-124E will pollster sales and allow its use against a wider range of medical conditions (some potentially for which it hasn’t even been tested against, as of yet). I still see a greater long term potential for IMM-529.
Hence why I continue to both acquire at these ridiculous lows and continue to hold.
Ann: Half Yearly Report and Accounts, page-4
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $22.79M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 10.0¢ | $11.40K | 114.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 130000 | 9.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 36972 | 1 |
View Market Depth
| Last trade - 11.02am 05/08/2024 (20 minute delay) ? |
| IMC (ASX) Chart |